Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (TRIBUTE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02579850
Recruitment Status : Completed
First Posted : October 20, 2015
Last Update Posted : March 6, 2019
Sponsor:
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

Brief Summary:
The aim of the present study is to evaluate the superiority of the fixed triple therapy with BDP/FF/GB at a daily dose of 400/24/50 mcg respectively with that of Ultibro® Breezhaler® (DPI), fixed combination of indacaterol 85 mcg and of glycopyrronium 43 mcg in COPD patients.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease (COPD) Drug: CHF 5993 + Ultibro matched placebo Drug: Ultibro + CHF 5993 matched placebo Procedure: Central spirometry Other: COPD assessment test Procedure: Local laboratory Assessments Other: Saint George's Respiratory Questionnaire Other: EXACT-pro questionnaire Phase 3

Detailed Description:

Outpatients attending the hospital clinics/study centres will be recruited. Patients with severe and very severe COPD airflow obstruction according to GOLD 2014 criteria. A total of approximately 2192 patients will need to be screened in order to obtain 1534 (767 per arm) randomized and evaluable patients. Approximately 200 sites will be involved worldwide.

Each patient will perform a total of 8 clinic visits (V0 to V7) during the study.

The Primary objective is to demonstrate the superiority of CHF 5993 pMDI over Ultibro® in terms of moderate and severe COPD exacerbation rate over 52 weeks of treatment.

The Secondary objectives are:

  1. To evaluate the effect of CHF 5993 pMDI on other lung function parameters, patient's health status and clinical outcome measures;
  2. To assess the safety and the tolerability of the study treatments.

A 2-week open-label run-in period under Ultibro® followed by a 52-week randomised treatment period.

The trial design will be optimised to measure exacerbation rates by using the Exacerbations of Chronic Pulmonary Disease Tool (EXACT), developed means of collecting patient-reported outcome (PRO) data, which helps to capture the frequency of exacerbations.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1532 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: 52-week, Double Blind, Randomized, 2 Active Parallel Arms Study of Fixed Combination CHF 5993 Administered vs Ultibro® in COPD Patients
Actual Study Start Date : May 29, 2015
Actual Primary Completion Date : July 10, 2017
Actual Study Completion Date : July 10, 2017

Arm Intervention/treatment
Experimental: CHF 5993 + Ultibro matched placebo

Fixed triple therapy with BDP/FF/GB 100/6/12.5 mcg (CHF 5993) administered 2 puffs twice daily via pMDI + Fixed combination of indacaterol and of glycopyrronium (Ultibro® Breezhaler®) matched placebo administered once daily via DPI for 52-week treatment.

Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.

7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments Saint George's Respiratory Questionnaire EXACT-pro questionnaire

Drug: CHF 5993 + Ultibro matched placebo
Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
Other Name: CHF 5993

Procedure: Central spirometry
Central spirometry to assess forced expiratory volume at one second and forced vital capacity

Other: COPD assessment test
COPD assessment test (CAT) at visit 1

Procedure: Local laboratory Assessments
ECG + Standard Haematology and Biochemistry

Other: Saint George's Respiratory Questionnaire
Saint George's Respiratory Questionnaire

Other: EXACT-pro questionnaire
daily from randomization (Visit 2) to end of study (Visit 7)

Active Comparator: Ultibro + CHF 5993 matched placebo

Fixed combination of indacaterol 85 mcg and of glycopyrronium 43 mcg (Ultibro® Breezhaler®) administered once daily via DPI + Fixed triple therapy with BDP/FF/GB (CHF 5993) matched placebo administered 2 puffs twice daily via pMDI for 52-week treatment.

Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.

7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments, Saint George's Respiratory Questionnaire, EXACT-pro questionnaire

Drug: Ultibro + CHF 5993 matched placebo
Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
Other Name: Ultibro Breezhaler

Procedure: Central spirometry
Central spirometry to assess forced expiratory volume at one second and forced vital capacity

Other: COPD assessment test
COPD assessment test (CAT) at visit 1

Procedure: Local laboratory Assessments
ECG + Standard Haematology and Biochemistry

Other: Saint George's Respiratory Questionnaire
Saint George's Respiratory Questionnaire

Other: EXACT-pro questionnaire
daily from randomization (Visit 2) to end of study (Visit 7)




Primary Outcome Measures :
  1. Moderate and severe COPD exacerbation rate over 52 weeks of treatment [ Time Frame: 1 year ]
    Exacerbations will be evaluated at each study visit and collected using EXACT-PRO filled-in by patient every day throughout the study


Secondary Outcome Measures :
  1. Time to first moderate to severe COPD exacerbation [ Time Frame: 1 year ]
  2. Rate of severe COPD exacerbation over 52 weeks of treatment [ Time Frame: 1 year ]
  3. Rate of moderate COPD exacerbation over 52 weeks of treatment [ Time Frame: 1 year ]
  4. Change from Baseline at each visit and over the entire treatment period in pre-dose morning FEV1 [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion :

  1. Male and female ≥ 40 years
  2. Severe or very severe COPD diagnosed for at least 12 months
  3. Current smokers or ex-smokers who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack years
  4. Post-bronchodilator FEV1 < 50% of the predicted normal value and a post-bronchodilator FEV1/FVC ratio < 0.7
  5. Documented history of at least one exacerbation in the 12 months
  6. Patient under double therapy for at least 2 months prior to screening. Double therapy will be defined by treatment with any of the following:

    Orally inhaled corticosteroid (ICS) and (long-acting beta2-agonist) LABA ICS and long-acting muscarinic antagonist (LAMA) Orally LABA and LAMA Monotherapy with LAMA for at least 2 months prior to screening

  7. Symptomatic patient at screening with a CAT score ≥ 10.
  8. Cooperative attitude and ability to use correctly the inhalers, the spacer AeroChamber Plus (only to patients who are using a spacer), the electronic devices with COPD questionnaire.

Exclusion :

  1. Pregnant or lactating women and all women physiologically capable of becoming pregnant UNLESS are willing to use one or more of the reliable methods of contraception
  2. Patient with a current clinical diagnosis of asthma with a physician-judged need for inhaled or oral corticosteroid therapy
  3. Patient requiring use of the following medications:

    Course of systemic steroids > 3 days for COPD exacerbation in the 4 weeks prior to screening Course of antibiotics for COPD exacerbation > 7 days in the 4 weeks prior to screening Phosphodiesterase-4 inhibitor in the 4 weeks prior to screening Use of antibiotics for a lower respiratory tract infection in the 4 weeks prior to screening

  4. COPD exacerbation requiring prescription of systemic corticosteroids and/or antibiotics or hospitalization during the run-in period
  5. Patient treated with non-cardioselective β-blockers in the month preceding the screening or during the run-in period.
  6. Patient treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as needed
  7. Patient requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia
  8. Known respiratory disorders other than COPD which may impact the efficacy of the study drug
  9. Patient who have clinically significant cardiovascular condition
  10. Patient with atrial fibrillation (AF): Paroxysmal atrial fibrillation, Persistent, Long standing or Permanent
  11. Abnormal and clinically significant 12-lead ECG that results in active medical problem which may impact the safety of the patient
  12. Patient whose ECG shows QTcF >450 ms for males or QTcF >470 ms for females at screening visit are not eligible (not applicable for patient with pacemaker)
  13. Medical diagnosis of narrow-angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction would prevent use of anticholinergic agents
  14. History of hypersensitivity to M3 Antagonists, β2-agonist, corticosteroids or any of the excipients contained in any of the formulations used in the trial which may raise contra-indications or impact the efficacy of the study drug
  15. Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug
  16. Patients with hypokalaemia (serum potassium <3.5 mEq/L or 3.5 mmol/L) or uncontrolled hyperkalaemia
  17. Unstable concurrent disease which may impact the results of the study
  18. Patients with any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next six months (after V1) or with malignancy for which they are currently undergoing radiation therapy or chemotherapy
  19. History of alcohol abuse or substance/drug abuse within 12 months prior to screening visit
  20. Participation in another clinical trial if investigational drug was received less than 8 weeks prior to screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02579850


Locations
Layout table for location information
Italy
Chiesi Farmaceutici S.p.A.
Parma, Italy, 43123
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
Investigators
Layout table for investigator information
Study Chair: Mario Scuri, MD Chiesi Farmaceutici S.p.A.
Principal Investigator: Nicolas Roche, Pr Hopitaux Universitaires Paris Centre - Groupe Hospitalier Cochin

Additional Information:
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier: NCT02579850     History of Changes
Other Study ID Numbers: CCD-05993AA1-08
2014-001704-22 ( EudraCT Number )
First Posted: October 20, 2015    Key Record Dates
Last Update Posted: March 6, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.

Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access Criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
URL: https://www.chiesi.com/en/chiesi-clinical-trial-data-request-portal/
Keywords provided by Chiesi Farmaceutici S.p.A.:
COPD
COPD Exacerbation
EXACT-PRO
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases